Global Severe Hypertriglyceridemia (SHTG) Therapeutics market size is predicted to grow from US$ 876 million in 2025 to US$ 2009 million in 2031; it is expected to grow at a CAGR of 14.8% from 2025 to 2031.

Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size, Share and Analysis

The global Severe Hypertriglyceridemia (SHTG) Therapeutics market size is predicted to grow from US$ 876 million in 2025 to US$ 2009 million in 2031; it is expected to grow at a CAGR of 14.8% from 2025 to 2031. Severe Hypertriglyceridemia (SHTG) is a medical condition characterized by abnormally high levels of triglycerides in the blood, which can lead to the development of cardiovascular diseases. SHTG is a serious condition that requires prompt treatment to reduce the risk of cardiovascular events such as heart attacks and strokes. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. LPI (LP Information) newest research report, the Severe Hypertriglyceridemia (SHTG) Therapeutics Industry Forecast looks at past sales and reviews total world Severe Hypertriglyceridemia (SHTG) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Severe Hypertriglyceridemia (SHTG) Therapeutics sales for 2025 through 2031. With Severe Hypertriglyceridemia (SHTG) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Severe Hypertriglyceridemia (SHTG) Therapeutics industry. This Insight Report provides a comprehensive analysis of the global Severe Hypertriglyceridemia (SHTG) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Severe Hypertriglyceridemia (SHTG) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Severe Hypertriglyceridemia (SHTG) Therapeutics market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Severe Hypertriglyceridemia (SHTG) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Severe Hypertriglyceridemia (SHTG) Therapeutics. This report presents a comprehensive overview, market shares, and growth opportunities of Severe Hypertriglyceridemia (SHTG) Therapeutics market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Oral &nbsp;&nbsp;&nbsp; Intravenous Injection Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital Pharmacy &nbsp;&nbsp;&nbsp; Retail Pharmacy &nbsp;&nbsp;&nbsp; Online Pharmacy This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Ionis Pharmaceuticals &nbsp;&nbsp;&nbsp; 89bio, Inc. &nbsp;&nbsp;&nbsp; Arrowhead Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; NorthSea Therapeutics B.V. &nbsp;&nbsp;&nbsp; Amryt Pharma &nbsp;&nbsp;&nbsp; Afimmune Pharmaceutical &nbsp;&nbsp;&nbsp; Zucara Therapeutics &nbsp;&nbsp;&nbsp; Novo Nordisk &nbsp;&nbsp;&nbsp; Adocia &nbsp;&nbsp;&nbsp; Pfizer Inc.

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size (2020-2031) &nbsp;2.1.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Severe Hypertriglyceridemia (SHTG) Therapeutics by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Segment by Type &nbsp;2.2.1 Oral &nbsp;2.2.2 Intravenous Injection &nbsp;2.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Type &nbsp;2.3.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Market Share by Type (2020-2025) &nbsp;2.4 Severe Hypertriglyceridemia (SHTG) Therapeutics Segment by Application &nbsp;2.4.1 Hospital Pharmacy &nbsp;2.4.2 Retail Pharmacy &nbsp;2.4.3 Online Pharmacy &nbsp;2.5 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application &nbsp;2.5.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Market Share by Application (2020-2025) 3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Player &nbsp;3.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Market Share by Player &nbsp;3.1.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue by Player (2020-2025) &nbsp;3.1.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Severe Hypertriglyceridemia (SHTG) Therapeutics by Region &nbsp;4.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Region (2020-2025) &nbsp;4.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Growth (2020-2025) &nbsp;4.4 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Growth (2020-2025) &nbsp;4.5 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country (2020-2025) &nbsp;5.2 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Type (2020-2025) &nbsp;5.3 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Region (2020-2025) &nbsp;6.2 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Type (2020-2025) &nbsp;6.3 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country (2020-2025) &nbsp;7.2 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Type (2020-2025) &nbsp;7.3 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics by Region (2020-2025) &nbsp;8.2 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Forecast &nbsp;10.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.1.3 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.1.4 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.1.5 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.2 Americas Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.2.2 Canada Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.2.3 Mexico Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.2.4 Brazil Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.3 APAC Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Region (2026-2031) &nbsp;10.3.1 China Severe Hypertriglyceridemia (SHTG) Therapeutics Market Forecast &nbsp;10.3.2 Japan Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.3.3 Korea Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.3.4 Southeast Asia Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.3.5 India Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.3.6 Australia Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.4 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.4.2 France Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.4.3 UK Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.4.4 Italy Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.4.5 Russia Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.5 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.5.2 South Africa Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.5.3 Israel Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.5.4 Turkey Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast &nbsp;10.6 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Type (2026-2031) &nbsp;10.7 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Severe Hypertriglyceridemia (SHTG) Therapeutics Forecast 11 Key Players Analysis &nbsp;11.1 Ionis Pharmaceuticals &nbsp;11.1.1 Ionis Pharmaceuticals Company Information &nbsp;11.1.2 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.1.3 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Ionis Pharmaceuticals Main Business Overview &nbsp;11.1.5 Ionis Pharmaceuticals Latest Developments &nbsp;11.2 89bio, Inc. &nbsp;11.2.1 89bio, Inc. Company Information &nbsp;11.2.2 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.2.3 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 89bio, Inc. Main Business Overview &nbsp;11.2.5 89bio, Inc. Latest Developments &nbsp;11.3 Arrowhead Pharmaceuticals, Inc. &nbsp;11.3.1 Arrowhead Pharmaceuticals, Inc. Company Information &nbsp;11.3.2 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.3.3 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Arrowhead Pharmaceuticals, Inc. Main Business Overview &nbsp;11.3.5 Arrowhead Pharmaceuticals, Inc. Latest Developments &nbsp;11.4 NorthSea Therapeutics B.V. &nbsp;11.4.1 NorthSea Therapeutics B.V. Company Information &nbsp;11.4.2 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.4.3 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 NorthSea Therapeutics B.V. Main Business Overview &nbsp;11.4.5 NorthSea Therapeutics B.V. Latest Developments &nbsp;11.5 Amryt Pharma &nbsp;11.5.1 Amryt Pharma Company Information &nbsp;11.5.2 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.5.3 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Amryt Pharma Main Business Overview &nbsp;11.5.5 Amryt Pharma Latest Developments &nbsp;11.6 Afimmune Pharmaceutical &nbsp;11.6.1 Afimmune Pharmaceutical Company Information &nbsp;11.6.2 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.6.3 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Afimmune Pharmaceutical Main Business Overview &nbsp;11.6.5 Afimmune Pharmaceutical Latest Developments &nbsp;11.7 Zucara Therapeutics &nbsp;11.7.1 Zucara Therapeutics Company Information &nbsp;11.7.2 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.7.3 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Zucara Therapeutics Main Business Overview &nbsp;11.7.5 Zucara Therapeutics Latest Developments &nbsp;11.8 Novo Nordisk &nbsp;11.8.1 Novo Nordisk Company Information &nbsp;11.8.2 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.8.3 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Novo Nordisk Main Business Overview &nbsp;11.8.5 Novo Nordisk Latest Developments &nbsp;11.9 Adocia &nbsp;11.9.1 Adocia Company Information &nbsp;11.9.2 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.9.3 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Adocia Main Business Overview &nbsp;11.9.5 Adocia Latest Developments &nbsp;11.10 Pfizer Inc. &nbsp;11.10.1 Pfizer Inc. Company Information &nbsp;11.10.2 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product Offered &nbsp;11.10.3 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Pfizer Inc. Main Business Overview &nbsp;11.10.5 Pfizer Inc. Latest Developments 12 Research Findings and Conclusion

Report	Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI50405

Buyer Information

Order Summary